by elasmogen | Jan 30, 2019 | News
Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
by elasmogen | Jan 7, 2019 | News
Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019: Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement...
